An inexpensive vitamin that improves cancer treatment would be worth taking seriously. That is why vitamin D attracted interest in colorectal cancer—and why the larger follow-up trial matters. Evidence-based integrative care has to make room for an encouraging early result becoming less convincing when tested more rigorously.
Evidence at a glance
Population: Previously untreated metastatic colorectal cancer. Formulation: Oral vitamin D3 added to chemotherapy and bevacizumab. Finding: SOLARIS did not establish improved cancer outcomes with high versus standard dosing. Separate question: Addressing deficiency and bone health can still be appropriate.
Why there was reason to investigate
The 2019 SUNSHINE phase II trial enrolled 139 people with advanced or metastatic colorectal cancer. Median progression-free survival was 13 months with high-dose vitamin D3 versus 11 months with standard dosing. The unadjusted comparison did not reach statistical significance (P=.07), although an adjusted analysis favored higher dosing. That was a signal to confirm, not a settled treatment recommendation.
A 2020 meta-analysis also reported favorable pooled results. However, it combined different settings and outcomes, including patients enrolled with colorectal cancer and people who developed it during population trials. Its search ended in January 2020. An older positive review cannot contain results that had not happened yet.
The larger trial
SOLARIS, published online August 3, 2026, randomized 455 patients receiving first-line FOLFOX or FOLFIRI chemotherapy plus bevacizumab. The high-dose arm used 8,000 IU daily for 14 days, then 4,000 IU daily; the comparison arm used 400 IU daily. These were monitored research regimens, not personal dosing instructions.
Median progression-free survival—the time before progression or death—was 11.8 versus 10.3 months (P=.25). Median overall survival was 25.6 versus 27.0 months. Tumor-response rates also did not differ significantly. The primary endpoint was negative.
Subtracting the two progression-free-survival medians does not establish that the supplement gave each person an extra 1.5 months. The trial did not demonstrate a reliable benefit. It compared two doses, not supplementation against no vitamin D, and does not answer every question about deficiency or earlier-stage disease.
Nutrition still has a job to do
The NIH Office of Dietary Supplements describes vitamin D’s established role in calcium absorption and bone health. Those are legitimate reasons to assess intake and, when clinically indicated, vitamin D status. They do not require a claim that higher dosing slows a tumor.
The distinction is practical: ask what problem a supplement is meant to solve. A plan for documented deficiency should have a goal and reassessment strategy. A plan advertised as cancer treatment needs evidence that it improves cancer outcomes. One cannot stand in for the other.
Safety is more than trial tolerability
SOLARIS found no clinically meaningful difference in common severe adverse events or vitamin D-related toxicities between groups. That is reassuring within the studied setting; it does not make unsupervised dose escalation harmless.
NIH guidance cautions that excessive supplementation can cause high calcium levels and kidney injury. The adult upper intake level is generally 4,000 IU daily, not a target everyone should reach; supervised treatment may differ. Calcium supplements, kidney function and medicines such as thiazide diuretics can affect the risk. Count vitamin D across all products rather than considering each bottle separately.
Practical questions for the care team
Are we treating deficiency, protecting bone health or hoping to affect the cancer? Is testing indicated in my situation? What total dose am I already getting? Does my kidney or calcium history change the plan? What result would lead us to reduce, stop or reassess supplementation?
Evidence checked October 20, 2026. Educational review, not individualized medical advice. Research doses and schedules are not personal prescriptions. Explore the Missing Script article library and the podcast—coming soon.
Vitamin D: put the negative trial beside the earlier signal
Evidence context: SOLARIS did not establish improved cancer outcomes with high-dose versus standard-dose vitamin D3 in metastatic colorectal cancer. Deficiency treatment and bone health are different clinical goals.
Open the evidence: High-dose vitamin D with chemotherapy for metastatic colorectal cancer · Nut consumption after stage III colon cancer
Bring to your visit: Ask about the reason for supplementation and appropriate monitoring; do not infer a personal dose from a research regimen.
See this topic in the Integrative Care Guide · How to read evidence labels
